Skip to main content

Table 3 Marginal effects of NI-T2D and coexisting diseases on the HRQoL of respondents as measured with the EQ-5D-5 L and EQ-5D-3 L crosswalk values

From: Impact of type 2 diabetes treated with non-insulin medication and number of diabetes-coexisting diseases on EQ-5D-5 L index scores in the Finnish population

Non-diabetics without coexisting diseases as reference group Difference in quality of life compared to non-diabetic persons with no coexisting diseases  
Category, number of coexisting diseases EQ-5D-5 L index score (95% CI) EQ-5D-3 L crosswalk index score (95% CI)
No T2D, 0 0 (reference) 0 (reference)
No T2D, 1 −0.053 (−0.061 to −0.046) −0.079 (−0.089 to −0.069)
No T2D, 2 −0.091 (− 0.103 to − 0.079) − 0.121 (− 0.135 to − 0.107)
No T2D, 3 − 0.100 (− 0.116 to − 0.083) −0.136 (− 0.155 to − 0.118)
No T2D, 4 ≥ −0.196 (− 0.235 to − 0.157) −0.227 (− 0.261 to − 0.193)
NI-T2D, 0 −0.015 (− 0.051 to 0.020) −0.021 (− 0.073 to 0.031)
NI-T2D, 1 − 0.060 (− 0.084 to − 0.036) −0.083 (− 0.113 to − 0.053)
NI-T2D, 2 −0.063 (− 0.084 to − 0.041) −0.086 (− 0.112 to − 0.060)
NI-T2D, 3 −0.097 (− 0.122 to − 0.073) −0.133 (− 0.160 to − 0.106)
NI-T2D, 4 ≥ −0.222 (− 0.279 to − 0.164) −0.247 (− 0.296 to − 0.199)
All non-diabetics together as reference group Difference in quality of life compared to non-diabetic persons  
Number of coexisting diseases EQ-5D-5 L index score (95% CI) EQ-5D-3 L crosswalk index score (95% CI)
No T2D 0 (reference) 0 (reference)
NI-T2D, 0 0.028 (−0.006 to 0.062) 0.039 (−0.012 to 0.090)
NI-T2D, 1 −0.014 (− 0.038 to 0.009) −0.020 (− 0.049 to 0.010)
NI-T2D, 2 − 0.013 (− 0.033 to 0.007) −0.019 (− 0.044 to 0.007)
NI-T2D, 3 − 0.043 (− 0.066 to − 0.019) −0.064 (− 0.091 to − 0.036)
NI-T2D, ≥4 −0.152 (− 0.207 to − 0.097) −0.170 (− 0.219 to − 0.121)
  1. Results were adjusted for age, sex, income, education, marital status, survey type and employment